Log in with your email address username.


[Comment] Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma?

In The Lancet, Martin Dreyling and colleagues1 present the results of a large, international, randomised phase 3 trial comparing the only two drugs approved for previously treated mantle cell lymphoma in Europe: temsirolimus and ibrutinib. Among 280 patients, those randomly assigned to daily oral ibrutinib 560 mg (n=139) showed a significant improvement in progression-free survival, the trial’s primary endpoint, compared with patients (n=141) assigned to daily intravenous temsirolimus 175 mg (14·6 months vs 6·2 months; hazard ratio 0·43 [95% CI 0·32–0·58]).